We at EBQ are so proud to have been part of these 2025 guidelines for AAV gene therapy for people with hemophilia.
We valued the opportunity to support WFH in bringing world class standards to the development of guidelines in this emerging yet increasingly important domain of a care for people with hemophilia.
Many thanks to the WFH staff, panelists, and other volunteers who assisted with this endeavor.
“The WFH Guidelines for the Management of Haemophilia: AAV Gene Therapy, 2025”